Improved diagnostics and intervention strategies for chronic autoimmune diseases in H2020 project
Thursday, June 30, 2016
Hycult Biotech participates in new H2020 project aiming at improved diagnostics and intervention strategies for chronic autoimmune diseases
(Uden, 18-02-2016) A new project funded by the European Commission (Horizon 2020) is devoted to research into chronic autoimmune diseases such as rheumatoid arthritis and vasculitis and the development of individualised therapies for affected patients. Hycult Biotech is part of the international project "RELENT", coordinated by MedUni Vienna (Renate Kain, Department of Pathology). The project started on 1 November 2015.
The objective of the project RELapses prevENTion in chronic autoimmune disease – common mechanisms and co-morbidities ("RELENT") is the development of improved therapies for chronic autoimmune diseases such as rheumatoid arthritis and vasculitis. A multidisciplinary consortium of nine scientific partners and four SME’s from Europe, the US and Australia is planning to research mechanisms common to these diseases which are responsible for the persistence and life-threatening developments of the diseases. The results of the study are intended for clinical application as soon as possible in order to help patients faster. Nearly six million Euros has been awarded to the RELENT consortium for the next 4.5 years by the European Commission under its Horizon 2020 programme.
Which patients will develop a severe course of autoimmune diseases?
Autoimmune diseases affect approximately five percent of the population in industrialised countries. In many cases, the disease has a mild progression, but they can also lead to a chronic and serious illness such as in the case of rheumatoid arthritis and other forms of arthritis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), multiple sclerosis, systemic Lupus erythematosus and various forms of systemic vasculitis.
Typically, these diseases progress in episodes; which requires long-term treatment with anti-inflammatory and immunosuppressive medications. These medications may have severe side effects, including an increased susceptibility for infections, cancer and cardiovascular diseases.
"There is currently no means to distinguish at the outset those patients who will suffer from frequent relapses, and therefore need intensive early treatment, from those who do not. Titrating the use of immunosupression to the disease activity and developing novel treatment strategies consequently requires the application of precision medicine to autoimmunity – a concept already established in cancer treatment,” states Prof. Renate Kain, coordinator of the project.
“RELENT is the next step in approaching personalized medicine and offers the potential of developing new treatments that are tailored to the specific needs of individual patients. Within RELENT we will focus on biomarkers that enable early monitoring and that will allow improvements in treatment strategies or predict progress of disease or outcome.“, states Dr. Erik Toonen, coordinator on behalf of Hycult Biotech.
“Hycult Biotech is always eager to participate in research projects and to be the connection between science and industry by jointly developing tools for monitoring chronic inflammatory diseases. Within the scope of RELENT we will be able to translate innovative findings into useful research tools and bring them to potential diagnostics.”, states Loek Willems, Business Development Manager, Hycult Biotech.
In order to better understand the common mechanisms of these diseases, the RELENT consortium will jointly analyse data from a variety of measurements (clinical, serological, genetic, transcriptome) and thus develop new bio-markers for these diseases. These should allow the tailoring of the most efficacious treatment to each patient with a chronic autoimmune disease.
The RELENT Consortium
MedUni Vienna is the coordinator of the consortium and is in charge of the project management together with GABO:mi. Further members of the consortium are the University of Cambridge (UK), University Medical Center Groningen (The Netherlands), Helmholtz-Zentrum München (Germany), the University Clinic of Bonn (Germany), Ludwig Maximilian University Munich (Germany), KTH Royal Institute of Technology (Sweden), Mayo Clinic (US), Monash University (Australia), EMC microcollections (Germany), Hycult Biotech (The Netherlands) and Phenocell (France).
Hycult Biotech is a leading world-class manufacturer of research reagents in the field of innate immunity. Products are co-developed with researchers around the globe. By connecting science with disease, these products offer innovative research solutions that enable better treatment, monitoring and prevention.
Hycult Biotech specializes in the development, manufacturing and commercialization of antibodies, proteins/peptides and assays. Within the focussed field of innate immunity special attention is dedicated to products relating to the complement system, antimicrobial peptides, neutrophil proteins, acute phase proteins, Toll-like receptors, cell – and tissue damage, LPS and oxidative stress.
About the Horizon 2020 Programme
Horizon 2020 is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020). It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. RELENT is funded as part of societal challenges “personalising health and care” in a specific call on “Understanding common mechanisms of disease and their relevance in co-morbidities”. In this call, the European Union emphasized that the development of new treatments is greatly facilitated by an improved understanding of the pathophysiology of diseases. RELENT is now addressing this need for better disease prevention, health promotion, therapy development and the management of co-morbidities for severe autoimmune and inflammatory diseases.
More information? www.relent.eu